Biotech

All Articles

Tracon winds down weeks after injectable PD-L1 prevention fall short

.Tracon Pharmaceuticals has chosen to wind down operations weeks after an injectable immune checkpoi...

Ideaya bags possibility on Biocytogen bispecific ADC in $400M package

.Ideaya Biosciences is actually wagering $400 million in biobucks that a bispecific antibody-drug co...

Takeda takes $140M loss on fallen short epilepsy medication, proclaims FDA run

.Our experts actually understand that Takeda is wanting to find a path to the FDA for epilepsy medic...

VBI Vaccinations apply for insolvency, seeks possession sale

.Immunology biotech VBI Injections is actually turning precariously near to the point of no return, ...

Celldex anti-cKIT antitoxin reduce hives in one more period 2 research

.It is actually challenging to muscle in on a room as very competitive as immunology, however Cellde...

Boehringer offers up to $1.3 B for checkpoint prevention biotech

.Boehringer Ingelheim is providing to $1.3 billion for Nerio Therapies and a preclinical immune gate...

Ventyx's last resort for inflamed med ends in Crohn's failing

.Ventyx Biosciences' Crohn's ailment medication carried out not help individuals obtain remission in...

Cognition's period 2 SHINE information taint Alzheimer's prospect

.Knowledge Therapeutics' period 2 SHINE test has actually taken some of the luster off the Alzheimer...

BMS axes bispecific months after submitting to operate stage 3 trial

.Bristol Myers Squibb has possessed a whiplash change of mind on its own BCMA bispecific T-cell enga...

Charles Baum takes over Terremoto as chief executive officer

.Charles Baum, M.D., Ph.D., that looked after Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squ...